NEC OncoImmunity (NOI), a subsidiary of NEC Corporation (NEC), and Vaximm AG, a Swiss/German biotech company focused on developing an oral plug and play DNA vaccination technology to stimulate patients' cytotoxic T-cells targeting a wide range of cancer-related antigens, announced that the companies have signed an agreement under which NOI will acquire all of Vaximm's neoantigen programme assets.
Japan based NEC Corporation, a leader in IT and network technologies, and VAXIMM AG, a Swiss/German biotech company focused on developing oral T-cell immunotherapies, announced that the companies have signed a strategic clinical trial collaboration agreement and an equity investment agreement to develop novel personalized neoantigen cancer vaccines.